The 20 Best Neuroblastoma Doctors Near Me in Ann Arbor, MI

Dr. Gregory Yanik has been a faculty member within the Blood and Marrow Transplant Program and Division at the University of Michigan since 1992. He was born and raised in the Detroit area, attended medical school at Wayne State University and trained in hematology-oncology at Cincinnati Children’s Hospital. He and his wife Marybeth have three grown children. Dr. Yanik has been the recipient of many prestigious awards in recognition of his contributions to medical research, clinical care, and education, including the Leland and Elaine Blatt Professorship of Pediatric Oncology, the University of Michigan Pediatric Teacher of the Year Award, and the Leukemia and Lymphoma Society Chairman’s Citation for Outstanding Service. Dr. Yanik is the founder of and chairs the Executive Committee for the Children’s Hematology Alliance of Michigan (CHAMI), a unique alliance of pediatric hematology/practice teams in the State of Michigan whose goal is to continuously improve the quality of care for children with these medical conditions regardless of where they are treated in the State. In addition to these many activities, Dr. Yanik makes time to serve on the Executive Committee for Make a Wish Michigan. Dr. Yanik is rated as an Elite provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

Rajen Mody is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Mody is rated as an Elite provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Infantile Neutropenia, Glioma, and Bone Marrow Aspiration.

Gary D. Hammer, M.D., Ph.D. is Professor in Departments of InternalMedicine (MEND), Cell & Developmental Biology, and Molecular &Integrative Physiology. He currently serves as Director of EndocrineOncology Program in Rogel Cancer Center where he holds the MillieSchembechler Professorship in Adrenal Cancer. He is past Director ofCenter for Organogenesis: Stem Cells & Regenerative Medicine. He hasbrokered the recent renaissance of the current Michigan team of adrenalscientists that includes a who’s who in the study of adrenal disease.He received the UofM Jerome Conn Award for Outstanding Research inInternal Medicine, the Endocrine Society Edwin B. Astwood Award forOutstanding Research and is a member of ASCI and AAP. He has served innumerous leadership roles at UofM and in the public and private sectorsincluding recent tenure on Board of Scientific Advisors for NCI. He isthe editor of four textbooks including Pathophysiology of Disease: AnIntroduction to Clinical Medicine (McGraw Hilll), and the upcomingAdrenal Section Editor for Degroot’s Endocrinology (Elsevier). He hasserved in numerous capacities for the world’s largest endocrineorganization, the Endocrine Society including his most recent role asPresident of the Society (2020-2021). An Advisor to the CongressionalH.E.L.P. committee - he co-authored the 21st Century Cancer ALERT(Access to Life-Saving Early detection, Research and Treatment) Act’’ lintroduced in Congress in 2009. He has been catalyst for the formationof two international cooperative groups, most recently the A5 (AmericanAustralian Asian Adrenal Alliance) that leverages collaboration tosecure projects from Pharma and funding agencies across the spectrum ofadrenal diseases. He is a cofounder of two companies - MILLENDO andSLING THERAPEUTICS that focus on rare endocrine diseases. Dr. Hammer is rated as a Distinguished provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Adrenal Cancer, Adrenocortical Carcinoma, Neuroblastoma, and Hereditary Neuroblastoma. Dr. Hammer is board certified in Endocrinology, Diabetes & Metabolism.

Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is rated as a Distinguished provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology.

Dr. Else’s primary appointment is with the Division of Metabolism, Endocrinology and Diabetes. He received his MD degree from the University of Hamburg, Germany. He pursued his clinical training at the University of Hamburg (Residency: Internal Medicine) and the University of Michigan (Residency: Internal Medicine, Fellowship: Endocrinology). His main research interests are the genetics of endocrine tumors. Dr. Else’s clinical practice focuses on the care for patients with benign and malignant endocrine tumors, particularly pheochromocytoma, adrenocortical tumors and neuroendocrine tumors as well as accompanying hormone excess syndromes (e.g Cushing syndrome, primary aldosteronism). Dr. Else has a particular interest in taking care of patients with hereditary syndromes that predispose to the development of endocrine tumors (e.g. Multiple Endocrine Neoplasia (MEN) type 1, MEN2A & MEN2B, Hereditary Paraganglioma Syndrome). He attends the Multidisciplinary Endocrine Oncology Clinic, where patients with tumors receive diagnostic procedures and treatment. In addition he is part of the Cancer Genetics Clinic, which evaluates patients for hereditary syndromes and also facilitates regular exams and surveillance for patients at risk for endocrine tumors. Dr. Else is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 105 other conditions, according to our data. His clinical expertise encompasses Adrenal Cancer, Adrenocortical Carcinoma, Adrenal Gland Adenoma, Neuroendocrine Tumor, and Thyroidectomy. Dr. Else is board certified in Internal Medicine and Endocrinology, Diabetes & Metabolism.

Valerie Opipari is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Opipari is rated as a Distinguished provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Hereditary Neuroblastoma, Acute Lymphoblastic Leukemia (ALL), Osteosarcoma, and Bone Marrow Aspiration.

Dr. Chun is a physician-scientist, who practices general endocrinology, including diabetes, thyroid diseases, and metabolic syndrome. His research is focused on the cellular and molecular mechanism of obesity, diabetes, and inflammatory and fibrotic tissue damages in endocrine disorders, such as Graves’ eye disease. Dr. Chun is rated as an Experienced provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Hyperparathyroidism, Neonatal Severe Hyperparathyroidism, Osteitis Fibrosa, and Familial Isolated Hyperparathyroidism. Dr. Chun is board certified in Endocrinology, Diabetes & Metabolism and Internal Medicine.

Nazanene H. Esfandiari, MD, is a Clinical Professor of Internal Medicine with an appointment in the Division of Metabolism, Endocrinology and Diabetes (MEND). Dr. Esfandiari received her medical degree from the University of Bordeaux in France, completed internal medicine residency in France and at UMASS Memorial Health Center in Massachusetts, and then completed fellowship in endocrinology at the University of Michigan. She joined the faculty at the University of Michigan in 2003. She was inducted into Clinical Excellence Society at the University of Michigan in 2014. She is the MEND Service Chief, Co-director of Hospital Intensive Insulin Program (HIIP) and Assistant Chief for the Inpatient Endocrine Consult.Dr. Esfandiari’s practice focuses on thyroid cancer, thyroid disorders, post bariatric care, and diabetes. She is also interested in medical education and is the Co-director of the Endocrine Sequence at the University of Michigan Medical School. In addition, Dr. Esfandiari has served in several national committees at the Endocrine Society and American Thyroid Association (ATA). Dr. Esfandiari is rated as an Experienced provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Thyroid Cancer, Follicular Thyroid Cancer, Anaplastic Thyroid Cancer, Gastric Bypass, and Thyroidectomy. Dr. Esfandiari is board certified in Endocrinology, Diabetes & Metabolism.

Rama Rao is a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Rao is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 36 other conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Chondrosarcoma, Hereditary Neuroblastoma, Neuroblastoma, and Bone Marrow Aspiration. Dr. Rao is board certified in Pediatric Hematology-Oncology.

Dr. Sedig was born and raised in Orlando, Florida. She completed her undergraduate degree in Medical Ethics at Davidson College before returning to Florida to attend the University of Florida College of Medicine. She then went to the University of Wisconsin-Madison for her residency in Pediatrics and then to the University of Michigan for her Pediatric Hematology/Oncology Fellowship. Dr. Sedig is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Retinoblastoma, Hepatoblastoma, Hereditary Neuroblastoma, Neuroblastoma, and Bone Marrow Aspiration.

Emily B. Walling MD, MPHS is a Clinical Assistant Professor in the Division of Hematology/Oncology, Department of Pediatrics. Dr. Walling received her bachelor's degree from the University of Wisonsin-Madison and her medical degree from the University of Toledo. Following residency training in pediatrics at the Medical College of Wisconsin, Dr. Walling completed her fellowship training in pediatric hematology-oncology at Washington University where she earned her master's degree in population health sciences. Dr. Walling joined the faculty at Michigan in 2016. She founded and is the co-medical director of the Michigan Medicine Adolescent and Young Adult Oncology Program. Dr. Walling is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Hereditary Neuroblastoma, Neuroblastoma, Osteosarcoma, and Bone Marrow Aspiration. Dr. Walling is board certified in Pediatric Hematology-Oncology and Pediatrics.

Joshua Goldman is a Pediatrics provider practicing medicine in Ann Arbor, Michigan. He has been practicing medicine for over 10 years. Dr. Goldman is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Hereditary Neuroblastoma, Febrile Neutropenia, and Bone Marrow Aspiration. Dr. Goldman is board certified in Pediatrics and Pediatric Hematology-Oncology.

Dr. Andrea (Flynn) Franson received her bachelor's degree from Rensselaer Polytechnic Institute in Troy, New York and her medical degree from the University of Michigan Medical School. She completed her residency in pediatrics and fellowship in pediatric hematology/oncology at the Children's Hospital of Philadelphia (CHOP). During fellowship, she earned a master's degree in Pharmacology from Thomas Jefferson University in Philadelphia. While at CHOP, she was an Alex's Lemonade Stand Foundation Center of Excellence Scholar, through which she had mentored training in clinical trial design and pharmacology. Dr. Franson has focused her research efforts in translational research science, working to transition the most promising compounds into the clinic for children with cancer. Dr. Franson is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Glioma, Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, Neuroblastoma, and Bone Marrow Aspiration.

My past and ongoing research is focused on translational studies and clinical trials for children with brain and spinal cord tumors with a special emphasis on ependymoma and ATRT. Children with brain tumors continue to have poor outcomes compared to those with other cancers in this age group. I have analyzed the outcomes of treatment for ATRT and ependymoma in children, combining traditional modes of therapy, such as surgery, chemotherapy, and radiation therapy, with molecularly targeted therapy. In the process we have identified novel clinical and molecular risk factors associated with outcomes. By identifying clinical risk factors associated with poor outcomes in these children, we can tailor therapy to improve outcomes in those at highest risk of treatment failures. Dr. Upadhyaya is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Teratoma of the Mediastinum, Glioma, Medulloblastoma, and Bone Marrow Aspiration.

Jennifer Agrusa is a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Agrusa is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Hereditary Neuroblastoma, Neuroblastoma, and Bone Marrow Aspiration. Dr. Agrusa is board certified in Pediatric Hematology-Oncology and Pediatrics.

Dr. Ghada Abusin was born in the Sudan and grew up in the United Arab Emirates (UAE). She received her medical degree in 2001 from the University of Khartoum, Sudan. In 2003, Dr. Abusin moved to the United States. She completed her pediatric residency training at the Children’s Hospital of New Jersey in Newark Beth Israel and pediatric hematology-oncology fellowship training at the University of Iowa Children’s Hospital. She joined the pediatric faculty at the University of Iowa after graduation in August 2011 and became the Co-Director of pediatric BMT program in 2012. During her time in Iowa, Dr. Abusin obtained both Master’s degree in Clinical Investigation and Certificate in Medical Education. Dr. Abusin is the recipient of the prestigious award 40 under 40 by the Corridor Business Journal in recognition of her contributions to pediatric bone marrow transplantation in the state of Iowa. Dr. Abusin is well known for her commitment and contributions to medical education for undergraduate students, medical students, pediatric residents and pediatric hematology/oncology fellows. She has served on the institutional review board (IRB) for human research for many years, exemplifying her understanding of the significance of research in medicine and the vital importance of protecting the rights and wellbeing of human life. Dr. Abusin joined the University of Michigan as a faculty member within the Blood and Marrow Transplant Program in the Department of Pediatrics in December 2016. Dr. Abusin is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Thalassemia, Neuroblastoma, Beta Thalassemia, and Bone Marrow Transplant.

Dr. Koschmann is a Pediatric Neuro-Oncologist in the Department of Pediatrics and a Principal Investigator of an independent translational Pediatric Neuro-Oncology laboratory. His work in the clinic and lab complement and drive each other, resulting in a clear goal to improve therapies for children with brain tumors. He has engaged in research and the clinical care of pediatric brain tumor patients at both Seattle Children’s Hospital and the University of Michigan’s Mott Children’s Hospital. The Koschmann laboratory is exploring the molecular mechanisms by which recurrent mutations in pediatric high-grade glioma (HGG), including glioblastoma (GBM), anaplastic astrocytoma (AA) and diffuse intrinsic pontine glioma (DIPG) promotes tumor formation and affect treatment response.Dr. Koschmann has applied this precision medicine approach in translational and clinical work in Pediatric Neuro-Oncology. Along with researchers and colleagues from multiple clinical divisions at the University of Michigan and other institutions, he developed and co-facilitate the UM CNS Precision Medicine conference. In this multi-disciplinary and multi-institutional conference, molecular results are incorporated from pediatric brain tumor patients (paired tumor/germline sequencing results and pre-clinical cell culture treatment studies) into their treatment. Dr. Koschmann has established new algorithms and are in the process of developing multiple clinical trials incorporating the use of molecularly targeted therapy for pediatric patients with brain tumors. He will serve as PI for these trials and their biologic correlative research. Dr. Koschmann is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Diffuse Midline Glioma H3 K27M-Mutant, Glioma, Brain Stem Cancer, and Embryonal Tumor with Multilayered Rosettes. Dr. Koschmann is board certified in Pediatric Hematology-Oncology and Pediatrics.

Mary Mcgrath is a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Mcgrath is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Factor 11 Deficiency, Hemophilia A, Hemophilic Arthropathy, and Glanzmann Thrombasthenia. Dr. Mcgrath is board certified in Pediatric Hematology-Oncology and Pediatrics.

Kelly Walkovich is a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Walkovich is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. She is also highly rated in 31 other conditions, according to our data. Her clinical expertise encompasses Hemophagocytic Lymphohistiocytosis, Infantile Neutropenia, Non-Langerhans-Cell Histiocytosis, and Histiocytosis.

Kirk Frey is a Neurologist and a Nuclear Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Frey is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Neuroendocrine Tumor, Osteopenia, and Hormone Replacement Therapy (HRT).